SCHEMBL7654833

SCHEMBL7654833

Cc1ccc(S(=O)(=O)NC(=O)c2ccc3nc(C)n(Cc4ccc(OCc5ccccc5)cc4Cl)c3c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.52
BCL2L1 Q07817 10/20 0.49
MCL1 Q07820 10/20 0.49
RORC P51449 1/20 0.43
HDAC1 Q13547 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
S1PR1 P21453 1/20 0.42
PRKX P51817 1/20 0.42
ACVR1 Q04771 1/20 0.42
S1PR5 Q9H228 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6307804 0.96 PPARG (0.54) PPARGBCL2L1MCL1RORCHDAC1
SCHEMBL6303378 0.93 PPARG (0.51) PPARGBCL2L1MCL1RORCHDAC1
SCHEMBL7654248 0.92 PPARG (0.52) PPARGBCL2L1MCL1RORCHDAC1
SCHEMBL7652842 0.90 PPARG (0.57) PPARGBCL2L1MCL1RORCHDAC1
SCHEMBL6301136 0.88 PPARG (0.62) PPARGBCL2L1MCL1RORCHDAC1
SCHEMBL6301141 0.88 PPARG (0.58) PPARGBCL2L1MCL1RORCHDAC1
SCHEMBL6307796 0.88 PPARG (0.54) PPARGBCL2L1MCL1HDAC1HDAC6
SCHEMBL6303634 0.88 PPARG (0.57) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL6301186 0.88 PPARG (0.55) PPARGRORCHDAC1HDAC6HDAC3
SCHEMBL6303321 0.87 PPARG (0.50) PPARGBCL2L1MCL1RORCHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP claimed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed